Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Oct 11 04:00PM ET
0.6936
Dollar change
-0.0160
Percentage change
-2.26
%
Index- P/E- EPS (ttm)-0.92 Insider Own1.85% Shs Outstand96.21M Perf Week-0.92%
Market Cap66.72M Forward P/E- EPS next Y-0.73 Insider Trans-0.16% Shs Float94.41M Perf Month-5.64%
Income-88.38M PEG- EPS next Q-0.35 Inst Own15.86% Short Float0.34% Perf Quarter-16.61%
Sales0.00M P/S- EPS this Y19.30% Inst Trans-13.09% Short Ratio6.81 Perf Half Y-50.06%
Book/sh0.82 P/B0.84 EPS next Y40.08% ROA-53.29% Short Interest0.32M Perf Year-70.61%
Cash/sh0.69 P/C1.01 EPS next 5Y21.22% ROE-72.64% 52W Range0.50 - 2.50 Perf YTD-63.60%
Dividend Est.- P/FCF- EPS past 5Y35.36% ROI-102.92% 52W High-72.26% Beta0.68
Dividend TTM- Quick Ratio3.29 Sales past 5Y0.00% Gross Margin- 52W Low38.05% ATR (14)0.06
Dividend Ex-Date- Current Ratio3.29 EPS Y/Y TTM14.69% Oper. Margin0.00% RSI (14)42.04 Volatility5.26% 8.35%
Employees104 Debt/Eq0.17 Sales Y/Y TTM- Profit Margin- Recom2.20 Target Price3.60
Option/ShortNo / Yes LT Debt/Eq0.09 EPS Q/Q-33.97% Payout- Rel Volume0.33 Prev Close0.71
Sales Surprise-28.70% EPS Surprise23.89% Sales Q/Q- EarningsJul 30 AMC Avg Volume47.26K Price0.69
SMA20-2.03% SMA50-14.39% SMA200-43.93% Trades Volume15,823 Change-2.26%
Date Action Analyst Rating Change Price Target Change
Jan-04-23Upgrade Societe Generale Hold → Buy
Dec-16-22Downgrade Goldman Neutral → Sell
May-10-22Downgrade Goldman Buy → Neutral $6 → $1.50
Sep-14-21Upgrade Societe Generale Hold → Buy
Jan-22-21Downgrade Societe Generale Hold → Sell
Nov-02-20Upgrade Societe Generale Sell → Hold
Aug-06-20Downgrade Societe Generale Buy → Sell
Aug-05-20Reiterated H.C. Wainwright Buy $25 → $14
Mar-17-20Downgrade Stifel Buy → Hold $18 → $6
Jan-09-20Upgrade Stifel Hold → Buy $10 → $18
Sep-23-24 04:30PM
Sep-04-24 04:30PM
Aug-02-24 04:30PM
Jul-30-24 08:55PM
05:30PM
04:30PM Loading…
04:30PM
Jul-29-24 01:30AM
Jul-08-24 04:30PM
Jun-05-24 04:30PM
Jun-04-24 04:30PM
May-31-24 09:51AM
May-30-24 04:30PM
May-17-24 04:30PM
May-16-24 04:30PM
May-09-24 04:30PM
11:53PM Loading…
May-07-24 11:53PM
04:30PM
Apr-25-24 04:30PM
Apr-04-24 04:43PM
Mar-08-24 11:01AM
09:33AM
Mar-07-24 10:52PM
04:30PM
Mar-04-24 04:30PM
Feb-20-24 04:30PM
Jan-16-24 04:30PM
Dec-04-23 04:30PM
Nov-09-23 04:30PM
Nov-06-23 04:30PM
Nov-02-23 04:30PM
04:30PM Loading…
Oct-31-23 04:30PM
Oct-27-23 04:30PM
Oct-16-23 02:00AM
Oct-05-23 04:30PM
Sep-05-23 04:30PM
Jul-31-23 04:25PM
Jul-25-23 04:30PM
Jul-19-23 04:30PM
Jul-10-23 04:30PM
Jun-16-23 04:30PM
Jun-08-23 04:30PM
Jun-06-23 05:00PM
May-10-23 05:30PM
May-09-23 04:30PM
May-04-23 04:30PM
Apr-19-23 05:09PM
Apr-12-23 04:30PM
Mar-24-23 04:30PM
Mar-13-23 01:30AM
Mar-07-23 04:30PM
Mar-02-23 05:30PM
04:30PM
Feb-27-23 01:30AM
Feb-21-23 04:30PM
Feb-10-23 04:30PM
Jan-23-23 04:30PM
Jan-04-23 04:30PM
Dec-23-22 01:30AM
Dec-08-22 04:30PM
Nov-22-22 04:30PM
Nov-09-22 01:30AM
Nov-03-22 04:30PM
Oct-31-22 04:30PM
Oct-20-22 04:30PM
Oct-03-22 04:30PM
Sep-21-22 05:45PM
Sep-07-22 04:30PM
Sep-02-22 04:30PM
Aug-10-22 04:50PM
Aug-01-22 04:30PM
Jul-27-22 04:30PM
Jul-20-22 04:30PM
Jun-28-22 06:15PM
Jun-16-22 01:30AM
Jun-09-22 02:55AM
Jun-07-22 04:30PM
May-17-22 04:30PM
May-12-22 04:30PM
May-04-22 07:30PM
May-02-22 05:00PM
04:00PM
Apr-25-22 07:30PM
04:30PM
Apr-21-22 04:30PM
Apr-14-22 04:30PM
Mar-14-22 04:30PM
Mar-11-22 04:30PM
Mar-09-22 04:30PM
Mar-03-22 04:15PM
Feb-24-22 04:30PM
Feb-22-22 04:30PM
Feb-14-22 04:30PM
Feb-09-22 04:30PM
Jan-21-22 04:30PM
Jan-18-22 05:38PM
01:38PM
Jan-12-22 04:30PM
Jan-07-22 01:30AM
Dec-20-21 04:15PM
Dec-10-21 04:30PM
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stephane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mohideen PharisChief Medical OfficerJul 29 '24Sale0.981,7851,74979,367Jul 31 05:32 PM
Mohideen PharisChief Medical OfficerMay 24 '24Sale1.3666089881,152May 29 04:15 PM
Mohideen PharisChief Medical OfficerMay 22 '24Sale1.3838252781,812May 29 04:15 PM
Tasse DanielCHIEF EXECUTIVE OFFICERMar 08 '24Buy0.8317,09414,18817,094Mar 11 04:15 PM
Ndu AdoraDirectorFeb 06 '24Buy0.891,8251,6241,825Feb 08 05:02 PM
Mohideen PharisChief Medical OfficerNov 22 '23Sale1.742,2453,90682,194Dec 19 04:44 PM